2810403A07Rik Activators
Chemical activators of KH domain containing 4, pre-mRNA splicing factor play a vital role in the modulation of splicing events within the cell. Bisindolylmaleimide I, for instance, targets protein kinase C (PKC), a kinase known to phosphorylate and reduce the activity of various splicing factors. By inhibiting PKC, Bisindolylmaleimide I allows for the upregulation of the splicing factors, thereby facilitating their activation. Similarly, SRPIN340 inhibits serine-arginine protein kinases (SRPKs), which are responsible for the phosphorylation of splicing factors. The inhibition provided by SRPIN340 prevents this hyperphosphorylation, leading to the active form of the splicing factors. TG003 acts in a comparable manner by selectively inhibiting Clk/Sty kinase, another kinase involved in the phosphorylation of splicing factors, thus promoting their active state. Indirubin-3'-monoxime takes on a broader approach by inhibiting cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3 (GSK-3), which can result in the activation of the splicing factors due to a change in their phosphorylation status.
Additionally, Harmine focuses on the inhibition of dual-specificity tyrosine phosphorylation-regulated kinase (DYRK), which when inhibited, can lead to the activation of the splicing factors. The compound 5-Iodotubercidin, an adenosine kinase inhibitor, may also indirectly contribute to the activation of splicing factors through the inhibition of other kinases. Flavopiridol, another CDK inhibitor, can prevent the phosphorylation of splicing factors, which is a necessary step for their activation. Cantharidin, by inhibiting protein phosphatases 1 and 2A, can lead to an increase in phosphorylation levels, which in turn, can activate splicing factors. C16, an inhibitor of the TGF-β type I receptor ALK5 kinase, may lead to the activation of splicing factors due to downstream effects on the signaling pathways that regulate splicing factor phosphorylation. Ellagic acid, by inhibiting DNA topoisomerases, may indirectly influence the activation of splicing factors. Lastly, Pladienolide B and Meayamycin, which bind to the spliceosome and inhibit the SF3b complex respectively, can change the assembly and composition of the splicing machinery, thus affecting the activity of splicing factors such as KH domain containing 4, pre-mRNA splicing factor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
As a specific inhibitor of protein kinase C (PKC), Bisindolylmaleimide I can upregulate splicing factors by inhibiting PKC which is known to phosphorylate and thereby reduce the activity of splicing factors including KH domain containing 4, pre-mRNA splicing factor, leading to its functional activation. | ||||||
SRPIN 340 | 218156-96-8 | sc-394310 | 10 mg | $226.00 | 1 | |
SRPIN340 is an inhibitor of serine-arginine protein kinases (SRPKs), which phosphorylate splicing factors. By inhibiting SRPKs, SRPIN340 prevents the hyperphosphorylation of splicing factors, which can result in the activation of KH domain containing 4, pre-mRNA splicing factor. | ||||||
Cdc2-Like Kinase Inhibitor, TG003 | 300801-52-9 | sc-202528 sc-202528A | 5 mg 25 mg | $139.00 $548.00 | 6 | |
TG003 is a specific inhibitor of Clk/Sty kinase, which phosphorylates serine/arginine-rich proteins involved in splicing. Inhibition of Clk/Sty by TG003 can lead to the activation of splicing factors like KH domain containing 4, pre-mRNA splicing factor by reducing hyperphosphorylation. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is a known inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3 (GSK-3). By inhibiting these kinases, it can lead to the activation of splicing factors, including KH domain containing 4, pre-mRNA splicing factor, through altered phosphorylation states. | ||||||
Harmine | 442-51-3 | sc-202644 sc-202644A sc-202644B sc-202644C sc-202644D sc-202644E sc-202644F | 250 mg 500 mg 1 g 10 g 50 g 100 g 500 g | $53.00 $104.00 $126.00 $551.00 $1467.00 $2611.00 $11455.00 | 2 | |
Harmine is an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase (DYRK), which can phosphorylate substrates involved in splicing. Its inhibition can activate splicing factors such as KH domain containing 4, pre-mRNA splicing factor by preventing their phosphorylation-mediated inactivation. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
5-Iodotubercidin is an adenosine kinase inhibitor that can also inhibit other kinases. Its action can lead to the accumulation of substrates for adenosine kinase, which may result in activation of splicing factors including KH domain containing 4, pre-mRNA splicing factor through indirect kinase inhibition. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a CDK inhibitor that may activate KH domain containing 4, pre-mRNA splicing factor by preventing phosphorylation by CDKs, which are known to regulate the activity of splicing factors through phosphorylation. | ||||||
Cantharidin | 56-25-7 | sc-201321 sc-201321A | 25 mg 100 mg | $89.00 $279.00 | 6 | |
Cantharidin is an inhibitor of protein phosphatases 1 and 2A. By inhibiting these phosphatases, it can lead to a net increase in protein phosphorylation, which can result in the activation of splicing factors like KH domain containing 4, pre-mRNA splicing factor by altering phosphorylation dynamics. | ||||||
Ellagic Acid, Dihydrate | 476-66-4 | sc-202598 sc-202598A sc-202598B sc-202598C | 500 mg 5 g 25 g 100 g | $58.00 $95.00 $245.00 $727.00 | 8 | |
Ellagic acid is known to inhibit the activity of DNA topoisomerases and as a result, may indirectly activate splicing factors such as KH domain containing 4, pre-mRNA splicing factor by altering cellular processes that rely on topoisomerase function, thus impacting splicing factor activity. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B binds to the spliceosome and could lead to the activation of splicing factors including KH domain containing 4, pre-mRNA splicing factor by changing the assembly and composition of the splicing machinery, thereby affecting its activity. | ||||||